Nex Eye
NEX-I is a pioneering biotech company specializing in cancer immunotherapy, focusing on developing first-in-class therapies that overcome resistance mechanisms in refractory cancers. With a strong emphasis on innovative platform technologies like ONCOKINE®, the company aims to set new standards in cancer treatment by actively inhibiting tumor growth and metastasis. NEX-I's mission is to lead the next era of cancer immunotherapy through cutting-edge research, strategic collaborations, and a commitment to improving patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Nex Eye
A-1611 16F, Tera tower 2, 201 Songpa-daero, Songpa-gu, Seoul, 05854, Republic of Korea
Products
Clinical-stage antibody candidate targeting a tumor microenvironment immunotherapy-resistance factor (partnered global development)
A monoclonal antibody clinical candidate that targets a tumor microenvironment factor implicated in resistance to immunotherapy; advanced into global development through an out-licensing partner.
Preclinical antibody candidate in IND-enabling development
A preclinical monoclonal antibody candidate targeting a tumor microenvironment resistance factor with ongoing translational testing and GLP toxicology to support IND submission.
Development-stage candidate with regulatory designation for a specific oncology indication
A development-stage candidate targeting a tumor microenvironment protein that has received a regulatory designation intended to provide development incentives for a specific cancer indication.
Clinical-stage antibody candidate targeting a tumor microenvironment immunotherapy-resistance factor (partnered global development)
A monoclonal antibody clinical candidate that targets a tumor microenvironment factor implicated in resistance to immunotherapy; advanced into global development through an out-licensing partner.
Preclinical antibody candidate in IND-enabling development
A preclinical monoclonal antibody candidate targeting a tumor microenvironment resistance factor with ongoing translational testing and GLP toxicology to support IND submission.
Development-stage candidate with regulatory designation for a specific oncology indication
A development-stage candidate targeting a tumor microenvironment protein that has received a regulatory designation intended to provide development incentives for a specific cancer indication.
Services
Discovery of tumor microenvironment targets using a validated discovery platform, followed by antibody generation, screening and selection of lead candidates for oncology indications; available via internal R&D or collaborative partnerships.
Execution of in vivo efficacy studies (including immune-resistant models), patient-derived ex vivo tissue testing, GLP toxicology studies and assembly of IND-supporting pharmacology and CMC documentation.
Collaborative ex vivo testing on patient tumor tissue combined with cloud-based analytics and AI to identify translational biomarkers, companion diagnostic hypotheses and mechanisms of response or resistance to therapeutic candidates.
Support for negotiation and execution of licensing and co‑development agreements, transfer of development programs to partner organizations, and preparation of partner-facing translational packages to enable global clinical advancement and commercialization.
Discovery of tumor microenvironment targets using a validated discovery platform, followed by antibody generation, screening and selection of lead candidates for oncology indications; available via internal R&D or collaborative partnerships.
Execution of in vivo efficacy studies (including immune-resistant models), patient-derived ex vivo tissue testing, GLP toxicology studies and assembly of IND-supporting pharmacology and CMC documentation.
Collaborative ex vivo testing on patient tumor tissue combined with cloud-based analytics and AI to identify translational biomarkers, companion diagnostic hypotheses and mechanisms of response or resistance to therapeutic candidates.
Support for negotiation and execution of licensing and co‑development agreements, transfer of development programs to partner organizations, and preparation of partner-facing translational packages to enable global clinical advancement and commercialization.
Expertise Areas
- Tumor microenvironment target discovery
- Therapeutic antibody discovery and engineering (including multispecifics and ADC evaluation)
- Translational ex vivo and in vivo preclinical model development
- Immune‑resistant in vivo tumor model development
Key Technologies
- Patient-derived organotypic tumor tissue platforms (PDOTS)
- Patient-derived xenograft (PDX) models
- Immune-resistant in vivo tumor models
- Monoclonal antibody generation and engineering
News & Updates
NEX-I's antibody candidate NXI-101 targeting immune-resistant factors in non-small cell lung cancer (NSCLC) has been selected for the Korea Drug Development Fund (KDDF) project, supporting its lead compound development.
NEX-I announced research results demonstrating the efficacy of NXI-101 in patient-derived tumor models, highlighting its potential to overcome immunotherapy resistance.
NEX-I has licensed its immunotherapy candidate NXI-101 to Ono Pharmaceutical, aiming for clinical development and commercialization worldwide.
NEX-I received the award for its contributions to innovative cancer immunotherapy development and successful licensing of NXI-101.
NEX-I's antibody candidate NXI-101 targeting immune-resistant factors in non-small cell lung cancer (NSCLC) has been selected for the Korea Drug Development Fund (KDDF) project, supporting its lead compound development.
NEX-I announced research results demonstrating the efficacy of NXI-101 in patient-derived tumor models, highlighting its potential to overcome immunotherapy resistance.
NEX-I has licensed its immunotherapy candidate NXI-101 to Ono Pharmaceutical, aiming for clinical development and commercialization worldwide.
NEX-I received the award for its contributions to innovative cancer immunotherapy development and successful licensing of NXI-101.